NCT03750513RecruitingPhase 1
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
Pilot Trial of LET Optimized IMPT for Pediatric Patients With Ependymoma
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 15 Nov 2018
- Start date
- 1 Apr 2019
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Childhood cancers
- NCT number
- NCT03750513
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 48
- From 1 Apr 2019 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with previous radiation therapy to the brain
- Disseminated ependymoma requiring craniospinal radiation therapy
Other
- Ependymoma of the spine
- Pregnancy
- Inability to undergo MR imaging
- Inability to receive gadolinium-based contrast agent
Who the study is looking for
- Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III
- Disease must be confined to the brain (no evidence of spread on MR imaging of the spine or on staging lumbar puncture)
- Patient may not receive chemotherapy concurrent with radiation
- Signed informed consent by patient and/or parents or legal guardian
- Lansky performance status score of 50 -100
Age in the registry: - to 22 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Cancer Center Coordinator of this site? Confirm its status | Boston | United States | Not yet recruiting |
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.